Zimmer Biomet Holdings Cash & Equivalents decreased by 28.3% to $424.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 69.4%, from $1.38B to $424.20M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -5.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
A universal metric for assessing a company's immediate financial health.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.04B | $919.60M | $378.10M | $435.80M | $386.40M | $545.40M | $375.70M | $330.20M | $319.80M | $292.10M | $415.80M | $393.00M | $420.10M | $569.00M | $525.50M | $1.38B | $556.90M | $1.29B | $591.90M | $424.20M |
| QoQ Change | — | -11.8% | -58.9% | +15.3% | -11.3% | +41.1% | -31.1% | -12.1% | -3.1% | -8.7% | +42.3% | -5.5% | +6.9% | +35.4% | -7.6% | +163.5% | -59.8% | +132.1% | -54.2% | -28.3% |
| YoY Change | — | — | — | — | -62.9% | -40.7% | -0.6% | -24.2% | -17.2% | -46.4% | +10.7% | +19.0% | +31.4% | +94.8% | +26.4% | +252.3% | +32.6% | +127.2% | +12.6% | -69.4% |